According to FutureWise analysis the market for acute intermittent porphyria is expected to register a CAGR of 6.1% from 2023-2031.
AIP, or acute intermittent porphyria, is an uncommon autosomal dominant condition marked by a deficiency of hydroxymethylbilane synthase (HMBS), a vital enzyme in heme synthesis. This condition exhibits various symptoms, such as abdominal pain, nausea, vomiting, peripheral neuropathy, and seizures. The primary treatment for acute AIP attacks involves intravenous administration of heme, which replenishes hepatic heme levels, reducing the production of porphyrin precursors and improving symptoms. In the event of an acute episode in a confirmed AIP patient, the initial approach typically involves providing a high carbohydrate diet or intravenous dextrose to inhibit hepatic ALAS1 transcription, a key enzyme in heme production. Pain can be managed with parenteral opiates, while nausea and vomiting can be controlled with specific medications. Tachycardia and hypertension can be addressed with appropriate medications like ACE- inhibitors, beta-blockers, and calcium channel blockers. In cases of seizures, drugs like diazepam, magnesium sulfate, or clonazepam are effective.
Specific treatment for AIP involves intravenous heme therapy (IHT), which promptly replenishes hepatic heme levels and reduces the production of porphyrin precursors. IHT should be quickly initiated in severe acute attacks and maintained for four days. Typically, a response is observed by the third day, with a decrease in urine and serum porphobilinogen levels. It's essential to administer Panhematin through a large vein to minimize the risk of phlebitis. While IHT is generally well-tolerated, caregivers should be aware of the associated risks with recurrent treatments.
FutureWise Market Research has published a report that provides an insightful analysis of Acute Intermittent Porphyria Market trends that are affecting the overall market growth. This report will provide a detailed analysis of market share, regional insights, and competitor analysis that includes stature of key manufacturers operational in this industry. By the end of the forecast period FutureWise research analysts' projects that the Acute Intermittent Porphyria Market will experience a significant growth. According to the analysis done, this report will help understand the information referring to the total valuation held by this industry. Additionally, this report will help in understanding the growth opportunities held by various segments of this market, further assist in making better strategic and expansion decisions by key stakeholders of an organization.